| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80053 |
Comprehensive metabolic panel |
20,731 |
15,788 |
$350K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
3,971 |
3,238 |
$338K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
4,250 |
3,258 |
$250K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,979 |
2,427 |
$234K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,569 |
1,215 |
$162K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,246 |
1,823 |
$148K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
23,734 |
17,440 |
$135K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,933 |
2,378 |
$83K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,182 |
3,372 |
$69K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
8,405 |
6,146 |
$62K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,383 |
2,673 |
$58K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,586 |
1,922 |
$52K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,664 |
2,052 |
$46K |
| 71046 |
Radiologic examination, chest; 2 views |
3,104 |
2,571 |
$45K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,891 |
2,947 |
$44K |
| 36415 |
Collection of venous blood by venipuncture |
7,988 |
6,141 |
$42K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
840 |
674 |
$41K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,068 |
893 |
$40K |
| 80061 |
Lipid panel |
3,841 |
3,295 |
$39K |
| 84484 |
|
6,552 |
4,097 |
$38K |
| 83880 |
|
2,267 |
1,704 |
$38K |
| 71045 |
Radiologic examination, chest; single view |
6,109 |
4,772 |
$38K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,261 |
2,683 |
$34K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
664 |
616 |
$31K |
| 84703 |
|
3,625 |
2,836 |
$30K |
| 87430 |
|
2,885 |
2,497 |
$29K |
| 86901 |
|
1,156 |
934 |
$26K |
| 73630 |
|
1,284 |
1,094 |
$26K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
3,712 |
3,004 |
$25K |
| 73560 |
|
1,134 |
1,008 |
$24K |
| 81001 |
|
8,508 |
6,632 |
$24K |
| 72100 |
|
1,021 |
874 |
$22K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
804 |
656 |
$21K |
| 87040 |
|
2,738 |
1,440 |
$21K |
| 74018 |
|
1,187 |
987 |
$20K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,810 |
2,435 |
$20K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
897 |
594 |
$20K |
| 87807 |
|
1,784 |
1,590 |
$20K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
564 |
502 |
$18K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
438 |
128 |
$18K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,966 |
1,488 |
$16K |
| 85027 |
|
3,083 |
2,580 |
$16K |
| 83690 |
|
3,093 |
2,397 |
$16K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,308 |
1,000 |
$13K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
356 |
99 |
$12K |
| 80320 |
|
782 |
615 |
$10K |
| 84702 |
|
1,088 |
849 |
$10K |
| 83605 |
|
1,470 |
982 |
$10K |
| 82962 |
|
2,923 |
1,286 |
$9K |
| 73030 |
|
562 |
481 |
$9K |
| 73130 |
|
450 |
378 |
$9K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
59 |
51 |
$7K |
| 87077 |
|
1,024 |
880 |
$7K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
569 |
417 |
$7K |
| 86850 |
|
918 |
755 |
$7K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,367 |
1,513 |
$6K |
| 87081 |
|
757 |
697 |
$6K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
38 |
27 |
$6K |
| 82553 |
|
921 |
653 |
$5K |
| 73610 |
|
332 |
308 |
$5K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
483 |
410 |
$5K |
| 72040 |
|
206 |
189 |
$5K |
| 83735 |
|
1,327 |
1,031 |
$5K |
| 86762 |
|
297 |
271 |
$5K |
| 81005 |
|
2,601 |
2,042 |
$5K |
| 87186 |
|
1,024 |
879 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,715 |
1,405 |
$5K |
| 71020 |
|
335 |
313 |
$5K |
| 80076 |
|
476 |
409 |
$5K |
| 86900 |
|
1,159 |
935 |
$5K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,218 |
995 |
$4K |
| 82550 |
|
1,029 |
726 |
$4K |
| 85730 |
|
999 |
799 |
$4K |
| 85610 |
|
1,660 |
1,306 |
$3K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
134 |
109 |
$3K |
| 86592 |
|
704 |
633 |
$3K |
| 87205 |
|
932 |
687 |
$3K |
| 71010 |
|
433 |
368 |
$3K |
| 86703 |
|
152 |
136 |
$3K |
| 85378 |
|
485 |
432 |
$2K |
| 82947 |
|
499 |
441 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
634 |
431 |
$2K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
15 |
12 |
$2K |
| 80050 |
General health panel |
45 |
43 |
$2K |
| 82150 |
|
431 |
375 |
$2K |
| 80143 |
|
104 |
78 |
$1K |
| 80179 |
|
91 |
66 |
$1K |
| 73502 |
|
74 |
67 |
$1K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
39 |
33 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
39 |
33 |
$1K |
| 73110 |
|
88 |
67 |
$1K |
| 71250 |
|
15 |
12 |
$1K |
| 87340 |
|
113 |
101 |
$1K |
| 93971 |
|
30 |
24 |
$1K |
| 72070 |
|
61 |
58 |
$1K |
| 87070 |
|
154 |
135 |
$1K |
| 82728 |
|
64 |
57 |
$997.71 |
| 84439 |
|
92 |
82 |
$964.60 |
| 85660 |
|
140 |
130 |
$939.85 |
| 84436 |
|
125 |
90 |
$889.30 |
| 87210 |
|
141 |
130 |
$732.70 |
| 86803 |
|
44 |
39 |
$709.79 |
| T1015 |
Clinic visit/encounter, all-inclusive |
61 |
38 |
$700.29 |
| 74000 |
|
39 |
29 |
$631.28 |
| 82565 |
|
66 |
54 |
$591.70 |
| 84480 |
|
40 |
27 |
$560.95 |
| 85379 |
|
98 |
64 |
$558.82 |
| 97001 |
|
14 |
12 |
$543.84 |
| 81025 |
|
91 |
85 |
$532.77 |
| 82677 |
|
14 |
14 |
$527.43 |
| 74010 |
|
33 |
26 |
$525.00 |
| 80164 |
|
17 |
12 |
$502.24 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
14 |
13 |
$452.77 |
| 74021 |
|
14 |
14 |
$375.79 |
| 82105 |
|
14 |
14 |
$365.72 |
| 82803 |
|
44 |
24 |
$359.19 |
| 84520 |
|
64 |
53 |
$334.29 |
| 86336 |
|
14 |
14 |
$332.43 |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
94 |
90 |
$312.48 |
| 82607 |
|
28 |
20 |
$281.48 |
| 36600 |
|
27 |
12 |
$278.11 |
| 70360 |
|
28 |
24 |
$272.28 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,591 |
1,023 |
$259.87 |
| 83540 |
|
36 |
30 |
$249.75 |
| 81003 |
|
167 |
156 |
$243.88 |
| 82746 |
|
14 |
12 |
$232.68 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
139 |
75 |
$219.21 |
| 84550 |
|
61 |
47 |
$207.65 |
| 97150 |
Therapeutic procedure(s), group (2 or more individuals) |
45 |
14 |
$174.03 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
90 |
69 |
$147.14 |
| 85651 |
|
41 |
38 |
$121.68 |
| 81002 |
|
52 |
50 |
$117.12 |
| 71271 |
|
16 |
14 |
$116.60 |
| 82270 |
|
30 |
29 |
$55.68 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
77 |
70 |
$43.52 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
175 |
150 |
$34.84 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
14 |
12 |
$29.83 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
623 |
441 |
$6.65 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
87 |
64 |
$5.92 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
1,523 |
1,101 |
$0.02 |
| J7050 |
Infusion, normal saline solution, 250 cc |
71 |
60 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
204 |
185 |
$0.00 |
| G0378 |
Hospital observation service, per hour |
296 |
216 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
30 |
25 |
$0.00 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
14 |
13 |
$0.00 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
18 |
14 |
$0.00 |